{"id":"gmm-2-ns","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GMM-2 NS appears to be an investigational agent in Phase 3 development by Glenmark Specialty. Without publicly disclosed mechanism details, the specific molecular target and pathway modulation remain unclear from available sources. The 'NS' designation may indicate a novel salt or specialized formulation.","oneSentence":"GMM-2 NS is a novel formulation designed to modulate immune or inflammatory pathways, though its exact mechanism requires further clinical characterization.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:12.147Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02870205","phase":"PHASE3","title":"Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2016-08","conditions":"Seasonal Allergic Rhinitis (SAR)","enrollment":1176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GMM-2 NS","genericName":"GMM-2 NS","companyName":"Glenmark Specialty S.A.","companyId":"glenmark-specialty-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}